P3 Health Partners Inc. PIII
7.05
0.00
0.00%
as of 25 Sep
- Market cap
- $51.2M
- P/E
- 0.0×
Follow PIII
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.02 | 0.01 | 0.01 | 0.02 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.59) | (0.37) | (0.44) | (1.90) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.09 | 0.20 | 0.18 | 0.17 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.03) | (3.47) | (2.84) | (1.99) | |
EV/FCF |
(1.03) | (3.47) | (2.84) | (1.96) | |
Quick Ratio |
0.43 | 0.30 | 0.22 | 0.29 | |
Current Ratio |
0.46 | 0.33 | 0.24 | 0.32 | |
Net Debt/EBITDA |
1.56 | 8.90 | (1.89) | (17.56) | |
Debt/Assets |
18.38% | 46.26% | 41.64% | 37.00% | |
Debt/Equity |
1.64 | (2.17) | (1.76) | (13.53) | |
Asset Turnover |
2.17 | 2.02 | 2.03 | 1.91 | |
Operating CF/Net income |
29.12 | (22.46) | 0.34 | 0.49 | |
Capex/Depreciation |
0.00 | 0.00 | 0.01 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
8.38% | 6.67% | 9.41% | 6.49% | |
Intangible Assets out of Total Assets |
0.69 | 0.70 | 0.75 | 0.75 | |
Share Based Compensation of Revenue |
0.22% | 0.27% | 0.29% | 0.35% | |
Graham Net Nets |
(11.07) | (63.74) | (59.50) | (19.37) | |
Graham Number |
141.85 | 194.60 | 219.76 | 71.90 | |
Earnings Yield |
(305.09%) | (1,251.62%) | (1,295.13%) | (448.94%) | |
Free Cash Flow Yield |
(359.73%) | (842.65%) | (800.56%) | (424.74%) | |
Revenue per Share |
114.93 | 117.52 | 117.72 | 105.65 | |
Operating CF per Share |
(18.42) | (8.35) | (7.87) | (4.72) | |
Capex per Share |
0.00 | 0.00 | 0.06 | (0.04) | |
Free Cash Flow per Share |
(18.42) | (8.35) | (7.81) | (4.75) | |
Cash per Share |
6.60 | 7.94 | 7.89 | 11.77 | |
Shareholders Equity per Share |
21.77 | (43.66) | (47.49) | (5.72) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
21.77 | (43.66) | (47.49) | (5.72) | |
Free Cash Flow |
(61.91) | (27.47) | (25.53) | (15.53) | |
Working Capital |
(209.24) | (353.27) | (412.17) | (288.32) | |
Capital Expenditures |
— | — | 0.20 | (0.12) | |
Net Current Asset Value |
(401.86) | (645.49) | (678.79) | (566.62) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(0.55%) | 0.32% | (19.62%) | (9.15%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
122.83 | 134.36 | 110.53 | 105.79 | |
Average Payables |
280.12 | 341.35 | 344.22 | 301.22 | |
Average Assets |
692.99 | 729.01 | 720.03 | 758.45 | |
Average Common Equity |
(23.39) | (40.15) | (39.65) | 50.91 |
Columns are period end dates